Mast cells impair host defense during murine Streptococcus pneumoniae pneumonia

Journal of Infectious Diseases

Volumn 210, Issue 9, 2014, Pages 1376-1384

  Van Den Boogaard, Florry E ^a   Brands, Xanthe ^a   Roelofs, Joris J T H ^a   De Beer, Regina ^a   De Boer, Onno J ^a   Van't Veer, Cornelis ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Inflammation; Lung; Mast cells; Pneumonia; Streptococcus pneumoniae

Indexed keywords

CROMOGLYCATE DISODIUM; DOXANTRAZOLE; TRYPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INFLAMMATION; INOCULATION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; WILD TYPE; WILD TYPE MOUSE; ANIMAL; C57BL MOUSE; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LUNG; MALE; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BACTERIAL LOAD; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; LUNG; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84922051619     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu285     Document Type: Article

References (42)

1. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991-2001.
2. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374:1543-56.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
5. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
6. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67:71-9.
7. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10:440-52.
8. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6:135-42.
9. Huang C, Friend DS, Qiu WT, et al. Induction of a selective and persistent extravasation of neutrophils into the peritoneal cavity by tryptase mouse mast cell protease 6. J Immunol 1998; 160:1910-9.
10. Ketavarapu JM, Rodriguez AR, Yu JJ, et al. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A 2008; 105:9313-8.
11. Sutherland RE, Olsen JS, McKinstry A, Villalta SA,Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol 2008; 181:5598-605.
12. Di NA, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170:2274-8.
13. Di NA, Yamasaki K, Dorschner RA, Lai Y, Gallo RL. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J Immunol 2008; 180:7565-73.
14. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNFalpha. Nature 1996; 381:77-80.
15. Xu X, Zhang D, Lyubynska N, et al. Mast cells protect mice from Mycoplasma pneumonia. Am J Respir Crit Care Med 2006; 173:219-25.
16. Cruse G, Fernandes VE, de SJ, et al. Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysin. J Immunol 2010; 184:7108-15.
17. van den Boogaard FE, Brands X, Schultz MJ, et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 9:122-32.
18. Schouten M, van 't Veer C, van den Boogaard FE, et al. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202:1600-7.
19. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989; 57:2037-42.
20. Knapp S, Wieland CW, van 't Veer C, et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 2004; 172:3132-8.
21. Lammers AJ, de Porto AP, Florquin S, et al. Enhanced vulnerability for Streptococcus pneumoniae sepsis during asplenia is determined by the bacterial capsule. Immunobiology 2011; 216:863-70.
22. van Zoelen MA, Schouten M, de Vos AF, et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182:4349-56.
23. Rijneveld AW, Weijer S, Bresser P, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34:1725-30.
24. Pejler G, Ronnberg E, Waern I, Wernersson S. Mast cell proteases: multifaceted regulators of infl ammatory disease. Blood 2010; 115: 4981-90.
25. Ramos L, Pena G, Cai B, Deitch EA, Ulloa L. Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol 2010; 185:709-16.
26. van den Wijngaard RM, Klooker TK, Welting O, et al. Essential role for TRPV1 in stress-induced (mast cell-dependent) colonic hypersensitivity in maternally separated rats. Neurogastroenterol Motil 2009; 21:1107-e94.
27. Chan CY, St John AL, Abraham SN. Plasticity in mast cell responses during bacterial infections. Curr Opin Microbiol 2012; 15:78-84.
28. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996; 381:75-7.
29. Thakurdas SM, Melicoff E, Sansores-Garcia L, et al. The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. J Biol Chem 2007; 282:20809-15.
30. Prussin C, Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111:S486-94.
31. Carvalho M, Benjamim C, Santos F, Ferreira S, Cunha F. Effect of mast cells depletion on the failure of neutrophil migration during sepsis. Eur J Pharmacol 2005; 525:161-9.
32. von Kockritz-Blickwede M, Goldmann O, Thulin P, et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 2008; 111:3070-80.
33. Barbuti G, Moschioni M, Censini S, Covacci A, Montecucco C, Montemurro P. Streptococcus pneumoniae induces mast cell degranulation. Int J Med Microbiol 2006; 296:325-9.
34. Mallen-St Clair J, Pham CT, Villalta SA, Caughey GH,Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004; 113:628-34.
35. Orinska Z, Maurer M, Mirghomizadeh F, et al. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med 2007; 13:927-34.
36. Seeley EJ, Sutherland RE, Kim SS, Wolters PJ. Systemic mast cell degranulation increases mortality during polymicrobial septic peritonitis in mice. J Leukoc Biol 2011; 90:591-7.
37. McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, Grencis RK. Mast cells disrupt epithelial barrier function during enteric nematode infection. Proc Natl Acad Sci U S A 2003; 100:7761-6.
38. Scudamore CL, Jepson MA, Hirst BH, Miller HR. The rat mucosal mast cell chymase, RMCP-II, alters epithelial cell monolayer permeability in association with altered distribution of the tight junction proteins ZO-1 and occludin. Eur J Cell Biol 1998; 75:321-30.
39. Groschwitz KR, Ahrens R, Osterfeld H, et al. Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc Natl Acad Sci U S A 2009; 106: 22381-6.
40. Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002; 109:1351-9.
41. Huang C, De Sanctis GT, O'Brien PJ, et al. Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung. J Biol Chem 2001; 276:26276-84.
42. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92:420-3.